California Public Employees Retirement System Uni Qure N.V. Transaction History

California Public Employees Retirement System

$135 Billion
Q2 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$29.97 - $37.17 $2.57 Million - $3.19 Million	-85,819 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$29.24 - $42.03 $232,194 - $333,760	-7,941 Reduced 8.47%	85,819 $2.89 Million
Q4 2020 Feb 02, 2021	BUY	$35.35 - $50.67 $299,237 - $428,921	8,465 Added 9.92%	93,760 $3.39 Million
Q3 2020 Nov 05, 2020	BUY	$35.98 - $47.66 $75,558 - $100,086	2,100 Added 2.52%	85,295 $3.14 Million
Q2 2020 Aug 12, 2020	BUY	$45.06 - $67.74 $261,122 - $392,553	5,795 Added 7.49%	83,195 $3.75 Million
Q1 2020 May 12, 2020	SELL	$40.01 - $73.97 $1.49 Million - $2.76 Million	-37,293 Reduced 32.52%	77,400 $3.67 Million
Q4 2019 Jan 27, 2020	BUY	$37.13 - $74.62 $1.25 Million - $2.51 Million	33,646 Added 41.51%	114,693 $8.22 Million
Q3 2019 Oct 31, 2019	BUY	$39.36 - $76.8 $1.35 Million - $2.64 Million	34,412 Added 73.79%	81,047 $3.19 Million
Q2 2019 Aug 15, 2019	SELL	$52.76 - $82.19 $55,450 - $86,381	-1,051 Reduced 2.2%	46,635 $3.65 Million
Q1 2019 May 03, 2019	SELL	$27.39 - $68.41 $10,956 - $27,364	-400 Reduced 0.83%	47,686 $2.84 Million
Q4 2018 Feb 08, 2019	SELL	$22.8 - $33.93 $45,600 - $67,860	-2,000 Reduced 3.99%	48,086 $1.39 Million
Q3 2018 Nov 13, 2018	BUY	$29.75 - $43.08 $644,355 - $933,069	21,659 Added 76.19%	50,086 $1.82 Million
Q2 2018 Aug 15, 2018	BUY	$21.96 - $39.94 $314,181 - $571,421	14,307 Added 101.32%	28,427 $1.08 Million
Q1 2018 May 11, 2018	BUY	$17.1 - $26.61 $241,452 - $375,733	14,120 New	14,120 $332,000

Others Institutions Holding QURE

# of Institutions

142

Shares Held

35.3M

Call Options Held

1.54M

Put Options Held

389K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.

Account